Scarica l'app Stockscreener
19.64
1.06%
-0.215
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
Catalyst Pharmaceuticals reaffirms $545M-$565M 2025 revenue guidance while accelerating FIRDAPSE oncology expansion - MSN
Catalyst Pharma Receives Buy Rating and Price Target of $34.00 from Bank of America Securities Analyst Jason Gerberry. - AInvest
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y - MSN
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Catalyst Pharmaceuticals Reports Strong Q2 2025 Earnings - TipRanks
Catalyst Pharma Updates Guidelines for SCLC Treatment - TipRanks
Transcript : Catalyst Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: Catalyst Pharmaceuticals Q2 2025 beats EPS forecast - Investing.com
Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years - 富途牛牛
Catalyst Pharmaceutical Partners Inc. Exceeds Q2 Earnings ExpectationsNews and Statistics - IndexBox
Catalyst Pharmaceuticals shares rise 1.70% premarket after Q2 revenue and adjusted EPS beat expectations. - AInvest
Catalyst Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Catalyst Pharmaceuticals reports Q2 EPS 68c, consensus 54c - TipRanks
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Catalyst Pharma Reports Record Q2 2025 Financial Results - TipRanks
Catalyst Pharmaceuticals earnings beat by $0.29, revenue topped estimates - Investing.com Canada
Catalyst Pharmaceuticals Q2 revenue, adjusted EPS beats expectations, reaffirms 2025 revenue guidance - MarketScreener
Catalyst Pharmaceuticals Reports Record Second Quarter and - GlobeNewswire
Catalyst Pharmaceuticals Announces Inclusion of VGCC Antibody Testing and Amifampridine in NCCN Guidelines for Small Cell Lung Cancer-Associated LEMS - Quiver Quantitative
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing - GlobeNewswire
90% of SCLC Patients Miss LEMS Diagnosis: NCCN Updates Guidelines with Critical Testing Protocol - Stock Titan
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? - MSN
Catalyst Pharmaceutics To Report Q2 Earnings: What's In The Cards? - Barchart.com
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - simplywall.st
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors - GlobeNewswire
Catalyst Pharma Appoints Dr. Curran to Board - TipRanks
Catalyst Pharmaceuticals Appoints Dr. Daniel Curran to Board of Directors - Quiver Quantitative
Ex-Takeda Rare Disease Chief Joins Catalyst Pharmaceuticals Board to Drive Strategic Growth - Stock Titan
What are the technical indicators suggesting about Catalyst Pharmaceuticals Inc.Skyrocketing returns - Jammu Links News
What are analysts’ price targets for Catalyst Pharmaceuticals Inc. in the next 12 monthsMarket-leading capital gains - Jammu Links News
What makes Catalyst Pharmaceuticals Inc. stock price move sharplyGet real-time alerts on high-potential stocks - Jammu Links News
Why is Catalyst Pharmaceuticals Inc. stock attracting strong analyst attentionDiscover stocks with superior performance - Jammu Links News
How does Catalyst Pharmaceuticals Inc. compare to its industry peersRealize consistent double-digit growth - Jammu Links News
What are the latest earnings results for Catalyst Pharmaceuticals Inc.Game-changing capital returns - Jammu Links News
How strong is Catalyst Pharmaceuticals Inc. company’s balance sheetFree Daily Trading Room Entry - Jammu Links News
When is Catalyst Pharmaceuticals Inc. stock expected to show significant growthUnlock rapid growth potential in your portfolio - Jammu Links News
What catalysts could drive Catalyst Pharmaceuticals Inc. stock higher in 2025Exceptional stock performance - Jammu Links News
What is the dividend policy of Catalyst Pharmaceuticals Inc. stockOutstanding stock performance - Jammu Links News
Is Catalyst Pharmaceuticals Inc. stock overvalued or undervaluedUnrivaled growth potential - Jammu Links News
Does Catalyst Pharmaceuticals Inc. stock perform well during market downturnsStock Strategy Insights For Fast Growth - Jammu Links News
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now? - Yahoo Finance
How many analysts rate Catalyst Pharmaceuticals Inc. as a “Buy”Free Stock Review Backed By Experts - Jammu Links News
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Can Traders Expect Breakout From Catalyst Pharmaceuticals Inc. This WeekSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen enviable returns of 404% over the past five years - Yahoo Finance
Zacks.com featured highlights Catalyst Pharmaceuticals, SunOpta, Gambling.com and Orion Group - The Globe and Mail
3.48%
0.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):